Measurement of cardiac biomarkers N/A 1,2,3,4 Evidence is still controversial. Periprocedural angina assessment 1,2 3,4 This is a potentially high-impact area with validated instruments, yet little data exist on how to best incorporate validated instruments into routine practice without excessive effort or costs. Aspirin/thienopyridine at discharge 3,4 1,2 There is little room for major impact or improvement, given existing evidence of already high compliance rates. *Corresponding numbers and letters are linked to the ACC/AHA Task Force on Performance Measures Attributes for Performance Measures. Numbers indicate the entire attribute, and letters indicate specific attribute subcriteria. yThese measures are performance measures. zIndicated in shading, these measures have been designated quality metrics. Quality metric are designated for use in internal quality-improvement programs only. These measures are not appropriate for any other purpose (e.g., pay-for-performance, physician ranking, or public reporting programs). xWhere applicable, the writing committee provided summary comments about why certain measures were included or not included in the final measure set. For all attributes noted as partially or does not fulfill attribute, the writing committee provided summary comments. ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; GFR, glomerular filtration rate; and PCI, percutaneous coronary intervention. Nallamothu et al. JACC Vol. 63, No. 7, 2014 ACC/AHA/SCAI/AMA-PCPI/NCQA February 25, 2014:722 45 Attributes and subcriteria key: 1. Evidence based: 1a. For structural measures, the structure should be closely linked to a meaningful process of care that in turn is linked to a meaningful patient outcome. 1b. For process measures, the scienti c basis for the measure is well established, and the process should be closely linked to a meaningful patient outcome. 1c. For outcome measures, the outcome should be clinically meaningful. 